ABI-2280 / Antiva Biosci - LARVOL DELTA

A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia (clinicaltrials.gov) - P1/2 | N=110 | Recruiting | Sponsor: Antiva Biosciences | N=29 ➔ 110 | Trial completion date: May 2024 ➔ Jun 2025 | Trial primary completion date: Apr 2024 ➔ Jun 2025

Enrollment change • Trial completion date • Trial primary completion date • Gynecology • Oncology • CDKN2A

Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts (clinicaltrials.gov) - P1/2 | N=160 | Recruiting | Sponsor: Antiva Biosciences | Trial completion date: Aug 2025 ➔ Feb 2026

Trial completion date • Human Papillomavirus Infection • Infectious Disease • Oncology

Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts (clinicaltrials.gov) - P1/2 | N=160 | Recruiting | Sponsor: Antiva Biosciences

New P1/2 trial • Human Papillomavirus Infection • Infectious Disease • Oncology

A Study of ABI-2280 Vaginal Tablet in Participants With Cervical Intraepithelial Neoplasia (clinicaltrials.gov) - P1/2 | N=29 | Recruiting | Sponsor: Antiva Biosciences | Trial completion date: Aug 2023 ➔ May 2024 | Trial primary completion date: Jul 2023 ➔ Apr 2024

Trial completion date • Trial primary completion date • Gynecology • Oncology • CDKN2A

Antiva Biosciences Closes $53 Million Series E Equity Financing Led by MPM-BioImpact Capital and Names Kristine Ball President and CEO (PRNewswire) - "Antiva Biosciences...announced the closing of a $53 million Series E equity financing....Proceeds from the financing, which will fund the company into late 2025, will support the advancement of the company's lead development candidate, ABI-2280, into key efficacy studies following completion of its ongoing Phase 1 trials. Planned studies include a Phase 2 clinical trial in high-grade cervical intraepithelial neoplasia (CIN 2,3) and an exploratory study as a potential treatment for high-risk HPV infection, specifically in subtypes that can lead to cancer."

Financing • Oncology

A Study of ABI-2280 Vaginal Tablet in Participants With Cervical Intraepithelial Neoplasia (clinicaltrials.gov) - P1/2 | N=29 | Recruiting | Sponsor: Antiva Biosciences | Not yet recruiting ➔ Recruiting

Enrollment open • Gynecology • Oncology • CDKN2A

A Study of ABI-2280 Vaginal Tablet in Participants With Cervical Intraepithelial Neoplasia (clinicaltrials.gov) - P1/2 | N=29 | Not yet recruiting | Sponsor: Antiva Biosciences

New P1/2 trial • Gynecology • Oncology • CDKN2A